- Lannett Company Inc LCI reported Q4 FY21 sales of $106 million, missing the consensus of $110.63 million.
- Sales decreased 23.1% Y/Y as Lannett's several key products faced a highly competitive pricing environment.
- For FY21, sales of $478.8 million missed the company's expectation of $480 million - $500 million.
- Adjusted gross margin for Q4 compressed to 25% from 35% a year ago.
- Adjusted operating income declined to $4.9 million compared with $26.7 million last year.
- Lannett posted a wider than expected net loss of $(0.19) than an estimated loss of $(0.12).
- Guidance: For FY22, Lannett sees sales of $400 million - $440 million, well below the Wall Street estimate of $472.06 million.
- It expects an adjusted gross margin of approximately 23% to 25% and an adjusted EBITDA of $40 million - $55 million.
- Related Content: Lannett Inks US Commercialization Pact For Spiriva Handihaler.
- Price Action: LCI shares are down 8.58% at $3.73 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechEarningsNewsPenny StocksGuidanceShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in